AusBioInvest 2023 connects innovators with investment


Australia’s premier life science investment conference attracts more than 280 delegates representing investors and life science professionals from 13 countries.

Kicking off Australia’s biggest week in biotech, investors and delegates flocked to Melbourne on Monday to hear the latest insights in life science investing and drive investment and partnership outcomes with local biotech companies.

As Australia’s pre-eminent life science investment event, AusBioInvest allows potential partners and investors, including global pharma representatives, to engage with Australia’s world-leading biotech companies as they present the latest, detailed information about their business cases and technologies.

The programme featured thought-provoking fireside chats with leading investors and business leaders, including Jennifer Nason, Global Chairman, Investment Banking, J.P. Morgan, who provided an update on global capital market trends, conditions and themes and what it means for Australian biotechs, while Gurkeerat Singh, Vice President Search and Evaluation, Eli Lilly, spoke on considerations US investors make when evaluating a \deal.

In a panel discussion chaired by Dr Amanda Gillon, Senior Partner, Bioscience Managers, experts discussed investment approaches to building Australia’s life science ecosystem, how to unlock the funds already in Australia (such as superannuation capital) to increase access to capital for biotech companies, and why it is critical to attract offshore investors to Australia.

Delegates also received an update and insights on public market conditions in Australia during a keynote from Ajita Tynan, Manager, Listed Company Services, Australian Securities Exchange (ASX).

AusBioInvest also connected key decision makers from the pharma and investment community, including venture capitalists, private equity firms and investment bankers, to hear pitches from 26 Australian biotech companies that are actively seeking investors or partners to support their funding and co-development.

Presenting companies included: Arovella Therapeutics (ASX:ALA), Avecho Biotechnology (ASX:AVE), BiomeBank, Carina Biotech, Celosia Therapeutics, Cyban, Dimerix (ASX:DXB), EBR Systems (ASX:EBR), Encapsolutions, ESFAM Biotech, FivepHusion, Genofax, Imagion Biosystems (ASX:IBX), Immuron Limited (ASX:IMC), InhaleRx (ASX:IRX), Invion (ASX: IVX), LBT Innovations (ASX:LBT), Microba, Noxopharm Limited (ASX:NOX), PolyActiva, Prescient Therapeutics (ASX:PTX), Respiri (ASX:RSH), Snoretox, TruScreen (ASX:TRU), Tessara Therapeutics, and Vaxxas.

AusBioInvest 2023 was rounded out with an exclusive Investor CEO dinner to provide a forum for presenting executives and investors to further network and discuss potential partnership opportunities.

AusBioInvest 2023 is proudly support by Host State Partner, the Victorian State Government. Thank you to AusBiotech’s Investment Advisory Group for their support in developing the programme.

Official event photography will be shared with delegates shortly.